Mirtazapine

Mirtazapine, the active ingredient in Mirtazapine, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirtazapine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for major depressive disorder, acting on the serotonergic and noradrenergic pathways to improve mood and functional capacity.

Major depressive disorder: reduces depressive symptoms and enhances overall wellbeing in adult patients.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal ideation, especially early in treatment - Seizures - Cardiovascular events such as arrhythmia

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: evaluate liver enzymes in patients with liver disease. - Monitor weight: watch for significant weight gain, especially in patients with metabolic risk. - Caution in elderly: increased sensitivity to sedation and orthostatic hypotension. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Contraindicated with MAO inhibitors: ensure a washout period of at least 14 days. - Pregnancy: risk category unknown, use only if benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin toxicity. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Carbamazepine: may reduce mirtazapine effectiveness. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Antihistamines: may enhance sedative effects. - Alcohol: can intensify central nervous system depression.